DUBLIN–(BUSINESS WIRE)–The “Global Protein Therapeutics Market Analysis 2019” report has been added to ResearchAndMarkets.com’s offering.
The Global Protein Therapeutics market is expected to reach $302,915.63 million by 2026 growing at a CAGR of 8.4% from 2018 to 2026.
Protein Therapeutics drugs are a significant class of medicines, which are administered to treat a variety of different diseases such as cancer, infectious diseases, and others. These drugs hold huge potential to improve human health.
Some of the factors such as the increasing predominance of chronic diseases and advancement of plasma-derived therapies are fuelling the market growth. However, stringent government regulations and high treatment costs per patient are restraining market growth.
Based on the product, the monoclonal antibodies segment has witnessed significant growth owing to the necessity and applicability of these products in the treatment of different chronic disorders. Monoclonal antibodies can be used alone or to carry drugs and radioactive or toxic substances directly to cancer cells. Monoclonal antibodies that are used as drugs assist the natural immune system’s function in fighting cancer. These medications may be used in combination with other cancer treatments.
The key vendors mentioned are Pfizer, Novo Nordisk, Merck, Johnson & Johnson, Generex Biotechnology, F. Hoffmann-La Roche, Eli Lilly, Baxter International, Amgen and AbbVie.
Key Questions Answered in this Report
- How this market evolved since the year 2016
- Market size estimations, forecasts and CAGR for all the segments presented in the scope
- Key Market Developments and financials of the key players
- Opportunity Analysis for the new entrants
- SWOT Analysis of the key players
- Fastest growing markets analyzed during the forecast period
Key Topics Covered
1 Market Synopsis
2 Research Outline
2.1 Research Snapshot
2.2 Research Methodology
2.3 Research Sources
2.3.1 Primary Research Sources
2.3.2 Secondary Research Sources
3 Market Dynamics
3.1 Drivers
3.2 Restraints
4 Market Environment
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Protein Therapeutics Market, By Product
5.1 Introduction
5.2 Monoclonal Antibody
5.3 Interferon
5.4 Insulin
5.5 Human Growth Hormone
5.6 Granulocyte-Colony Stimulating Factor (G-CSF)
5.7 Fusion Protein
5.8 Follicle-Stimulating Hormone
5.9 Erythropoietin
5.10 Blood Clotting Factor
6 Global Protein Therapeutics Market, By Protein Function
6.1 Introduction
6.2 Vaccines
6.3 Protein Diagnostics
6.4 Enzymatic and Regulatory
7 Global Protein Therapeutics Market, By Application
7.1 Introduction
7.2 Protein Vaccine
7.3 Metabolic and Endocrine Disorders
7.4 Infectious Diseases
7.5 Immunological Disorders
7.6 Hormonal Disorders
7.7 Hematological Disorders
7.8 Genetic Disorders
7.9 Cancer
7.10 Other Applications
8 Global Protein Therapeutics Market, By Geography
8.1 Introduction
8.2 North America
8.3 Europe
8.4 Asia-Pacific
8.5 South America
8.6 Middle East & Africa
9 Strategic Benchmarking
10 Vendors Landscape
10.1 Pfizer
10.2 Novo Nordisk
10.3 Merck
10.4 Johnson & Johnson
10.5 Generex Biotechnology
10.6 F. Hoffmann-La Roche
10.7 Eli Lilly
10.8 Baxter International
10.9 Amgen
10.10 AbbVie
For more information about this report visit https://www.researchandmarkets.com/r/uv9f36
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900